Specification

IVISense[™] Integrin Receptor 645 Fluorescent Probe

Product Number: NEV10640

DESCRIPTION

IVISense^M Integrin Receptor 645 Fluorescent Probe is a targeted fluorescence imaging agent comprising a potent, selective non-peptide small molecule integrin $\alpha_{\nu}\beta_{3}$ antagonist and an NIR fluorochrome. This agent has been developed to enable in vivo visualization and quantification of integrin $\alpha_{\nu}\beta_{3}$ expression in neovasculature as well as in tumor cells, to monitor tumor angiogenesis, growth, and treatment efficacy. Half-life in tissue of IVISense^M

Integrin Receptor 645 Fluorescent Probe signal is approximately 2 days.

MATERIAL

Each vial contains 24 nmol of IVISenseTM Integrin Receptor 645 Fluorescent Probe as a 20 μ M solution in 1 x PBS which has been filtered through a 0.2 μ m filter prior to filling. The solution is ready for injection. The packaged material provides sufficient reagent for imaging approximately 10 mice (weighing ~25 grams each) when using the recommended dose of 2 nmol (100 μ L) of IVISenseTM Integrin Receptor 645 Fluorescent Probe per mouse.

STORAGE & HANDLING

- Upon receipt, IVISense[™] Integrin Receptor 645 Fluorescent Probe should be IMMEDIATELY STORED AT 2-8 °C AND PROTECTED FROM LIGHT.
- When stored and handled properly, IVISense[™] Integrin Receptor 645 Fluorescent Probe is stable for up to 3 months as a PBS solution at 2-8°C and protected from light, from the date of shipment.

IN VIVO IMAGING & APPLICATIONS

 MW
 ~1250 g mol⁻¹

 Fluorescence¹
 649 nm

 • Excitation
 649 nm

 • Emission
 666 nm

 Absorbance¹
 649 nm

 Purity²
 >90%

 Appearance
 Clear blue solution

 . Absorbance, excitation, and fluorescence maxima of in

Property

 Absorbance, excitation, and fluorescence maxima of in 1xPBS.

2. As determined by RP-HPLC, measuring absorbance at 645nm



- The recommended procedure for in vivo imaging with IVISense™ Integrin Receptor 645 Fluorescent Probe is administration via intravenous injection and imaging 6-24 hours post injection.
- Imaging maybe performed as early as 3 hours with some reduction in target signal/noise. It will clear from tissues after approximately 6-+7 days. Repeat injection and imaging may be performed every 3 days for longitudinal studies.
- IVISense[™] Integrin Receptor 645 Fluorescent Probe enables imaging of neovasculature and tumors in a range of oncology applications.

Revvity, Inc. 940 Winter Street

Waltham, MA 02451 USA

(800) 762-4000 www.revvity.com For a complete listing of our global offices, visit <u>www.revvity.com</u> Copyright ©2023, Revvity, Inc. All rights reserved.

The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS, OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF NEVTONE CONTAINED HEREIN OR THE PRODUCT ITSELF.